GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030511 describes any process that activates or increases the frequency, rate or extent of TGF-beta receptor signaling pathway activity.
• The pathway is initiated when TGF-beta ligands bind TGF-beta type II receptor (TGFBR2), which recruits and phosphorylates TGF-beta type I receptor (TGFBR1/ALK5).
• Positive regulation can occur at the receptor level through stabilization of TGFBR1 by receptor-associated adaptors, or through ligand-receptor positive feedback loops.
• Dysregulated positive regulation of TGF-beta receptor signaling is linked to cancer stemness, drug resistance, metastasis, and immune evasion.
• Key genes involved include TGFB1, TGFBR1, TGFBR2, SMAD2, SMAD3, SMAD4, and accessory receptors such as ENG and GPR56.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential for dissecting causal roles of genes in this pathway.
Description
The Gene Ontology term GO:0030511, positive regulation of transforming growth factor beta receptor signaling pathway, captures the biological processes that enhance or sustain signaling downstream of TGF-beta receptor activation. TGF-beta signaling is a fundamental pathway controlling cell proliferation, differentiation, apoptosis, and immune regulation, and its positive regulation is critical for both normal development and disease progression. Understanding how this pathway is amplified at the receptor level provides mechanistic insights into cancer, fibrosis, and immune disorders. Researchers studying this term aim to identify the molecular players that boost TGF-beta receptor activity, such as adaptor proteins, co-receptors, and feedback loops. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0030511, its core mechanisms, key genes, disease relevance, and experimental strategies for investigation.
positive regulation of transforming growth factor beta receptor signaling pathway At A Glance
| GO ID | GO:0030511 |
|---|---|
| GO term | positive regulation of transforming growth factor beta receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activation of transforming growth factor beta receptor signaling pathway; positive regulation of TGF-beta receptor signaling pathway; stimulation of transforming growth factor beta receptor signaling pathway; upregulation of transforming growth factor beta receptor signaling pathway |
| Major function | Enhances TGF-beta receptor signaling by stabilizing receptors, promoting ligand-receptor interactions, or amplifying downstream SMAD activation |
| Related pathways | TGF-beta signaling, SMAD-dependent signaling, receptor tyrosine kinase crosstalk |
| Cellular location | Plasma membrane, early endosomes, cytoplasm, nucleus |
| Key regulators | TGFBR1, TGFBR2, SMAD2/3/4, accessory proteins such as GPR56 and adaptors |
What Is GO:0030511?
GO:0030511 is defined as any process that activates or increases the frequency, rate or extent of TGF-beta receptor signaling pathway activity. In other words, it encompasses molecular events that positively regulate the canonical signaling cascade triggered by TGF-beta family ligands binding to their cell-surface receptors, leading to downstream SMAD activation and transcriptional responses.
Why Is positive regulation of transforming growth factor beta receptor signaling pathway Important in Cell Biology?
Positive regulation of TGF-beta receptor signaling is central to a wide range of physiological and pathological processes. It controls embryonic development, tissue homeostasis, and immune responses, but its aberrant activation drives cancer progression, metastasis, fibrosis, and immune evasion. Understanding the mechanisms that positively regulate this pathway is therefore essential for identifying therapeutic targets and designing interventions that modulate TGF-beta signaling in disease.
• Drives cancer stemness and drug resistance in liver cancer through stabilization of TGFBR1.
• Promotes metastasis in hepatocellular carcinoma via GPR56-mediated enhancement of TGF-beta signaling.
• Suppresses type 2 immunity to cancer, contributing to immune evasion.
• Correlates with poor prognosis in glioblastoma, IDH-wildtype, through TGF-beta receptor expression.
• Facilitates Nodal signaling propagation via receptor interactions and positive feedback.
• Plays a role in HCV-related hepatocellular carcinoma aggressiveness through crosstalk with type 2 TGF-beta receptor.
• Influences tissue-resident memory CD8 T cell formation via GPR25.
• Provides targets for CRISPR-based functional genomics in cancer and immunology.
What Happens During positive regulation of transforming growth factor beta receptor signaling pathway?
Ligand binding and receptor complex formation
In simple terms: TGF-beta ligands attach to receptors on the cell surface, bringing them together to start signaling.
The pathway begins when TGF-beta family ligands, such as TGFB1, bind to the extracellular domain of TGF-beta type II receptor (TGFBR2), a constitutively active serine/threonine kinase. This binding recruits and phosphorylates TGF-beta type I receptor (TGFBR1/ALK5), forming an active receptor complex. Positive regulation at this stage can involve increasing ligand availability, enhancing receptor affinity, or stabilizing the receptor complex.
Receptor stabilization and adaptor-mediated enhancement
In simple terms: Helper proteins can protect the receptor from degradation, making signaling stronger and longer.
Receptor-associated adaptor proteins can stabilize TGFBR1, preventing its degradation and thereby sustaining downstream signaling. For example, in liver cancer stem cells, an adaptor protein stabilizes TGFBR1 to maintain feedback activation of the TGF-beta pathway, contributing to drug resistance. This represents a direct positive regulation mechanism at the receptor level.
SMAD phosphorylation and signal amplification
In simple terms: The activated receptor turns on SMAD proteins, which carry the signal to the nucleus.
Activated TGFBR1 phosphorylates SMAD2 and SMAD3, which then form complexes with SMAD4 and translocate to the nucleus to regulate gene expression. Positive regulation can amplify this step by increasing SMAD phosphorylation or enhancing SMAD complex stability. Feedback loops, such as those involving inhibitory SMADs, are also subject to positive regulation to fine-tune signaling intensity.
Positive feedback loops and pathway propagation
In simple terms: The pathway can boost itself by producing more of its own components.
Positive feedback regulation occurs when TGF-beta signaling induces the expression of pathway components or co-receptors that further enhance signaling. For instance, Nodal signaling propagation is regulated by receptor interactions and positive feedback, which amplifies the signal. Similarly, GPR56 promotes hepatocellular carcinoma metastasis by enhancing TGF-beta signaling, likely through a positive feedback mechanism.
Crosstalk with other signaling pathways
In simple terms: Other signals can talk to the TGF-beta pathway and make it stronger.
Positive regulation of TGF-beta receptor signaling can also occur through crosstalk with other pathways. For example, down-regulation of GHR/STAT5/IGF-1 signaling is associated with increased type 2 TGF-beta receptor expression in HCV-related hepatocellular carcinoma, suggesting a regulatory network that influences TGF-beta signaling. Additionally, GPR25 promotes tissue-resident memory CD8 T cell formation, potentially through modulation of TGF-beta signaling.
Key Genes Involved in GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway
The following genes and proteins are central to the positive regulation of TGF-beta receptor signaling, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Ligand that initiates TGF-beta receptor signaling | Target for modulating pathway activation in cancer and fibrosis |
| TGFBR1 | Type I receptor kinase; phosphorylates SMAD2/3 | Stabilization enhances signaling; target for knockout and point mutation studies |
| TGFBR2 | Type II receptor; binds ligand and activates TGFBR1 | Expression levels correlate with cancer prognosis |
| SMAD2 | Receptor-regulated SMAD; transduces signal to nucleus | Key effector; knockout models reveal pathway dependence |
| SMAD3 | Receptor-regulated SMAD; forms complexes with SMAD4 | Critical for transcriptional responses; point mutations affect activity |
| SMAD4 | Common SMAD; essential for SMAD complex function | Frequently mutated in cancers; knockout impairs signaling |
| GPR56 | Adhesion G protein-coupled receptor; promotes TGF-beta signaling | Enhances HCC metastasis; overexpression models |
| GPR25 | G protein-coupled receptor; involved in T cell residency | Potential modulator of TGF-beta in immune cells |
| ENG | Accessory receptor; modulates TGF-beta signaling | Regulates pathway activity; knockout models available |
| NODAL | TGF-beta family ligand; activates receptor complexes | Positive feedback regulation in development |
| SMAD7 | Inhibitory SMAD; negative feedback regulator | Its downregulation can enhance positive regulation |
| SKI | Transcriptional co-repressor; interacts with SMADs | Modulates pathway output; knockout studies |
| SNON | Transcriptional co-repressor; interacts with SMADs | Regulates TGF-beta target genes |
| PPM1A | Phosphatase that dephosphorylates SMADs | Negative regulator; its inhibition enhances signaling |
| UBE2D | E2 ubiquitin-conjugating enzyme; regulates receptor turnover | Affects receptor stability and positive regulation |
| USP | Deubiquitinase; stabilizes TGFBR1 | Potential adaptor-mediated stabilization |
| CD109 | Co-receptor; modulates TGF-beta signaling | Regulates pathway activity in cancer |
| LTBP1 | Latent TGF-beta binding protein; regulates ligand availability | Controls positive regulation at the ligand level |
How Is positive regulation of transforming growth factor beta receptor signaling pathway Regulated?
Positive regulation of TGF-beta receptor signaling is itself tightly regulated by multiple mechanisms. Receptor stability is controlled by ubiquitination and deubiquitination, with adaptor proteins preventing degradation of TGFBR1 to sustain signaling. Feedback loops involving inhibitory SMADs, such as SMAD7, provide negative regulation that can be overcome by positive regulators. Additionally, crosstalk with other pathways, such as GHR/STAT5/IGF-1, can influence TGF-beta receptor expression and activity. Positive feedback loops, as seen in Nodal signaling, further amplify the pathway.
positive regulation of transforming growth factor beta receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR1 | Liver cancer stemness and drug resistance | Knockout and point mutation in liver cancer cell lines |
| GPR56 | Hepatocellular carcinoma metastasis | Overexpression and knockout in HCC cells |
| TGFBR2 | Glioblastoma prognosis | Knockdown and overexpression in glioblastoma cells |
| GPR25 | T cell residency and immunity | Knockout in CD8 T cells |
| NODAL | Developmental signaling | Knock-in reporter and point mutation in zebrafish or cell lines |
Cancer progression and metastasis
Aberrant positive regulation of TGF-beta receptor signaling promotes cancer stemness, drug resistance, and metastasis. In liver cancer, stabilization of TGFBR1 by an adaptor protein maintains cancer stemness and drug resistance. GPR56 facilitates hepatocellular carcinoma metastasis by promoting TGF-beta signaling. In glioblastoma, IDH-wildtype, TGF-beta receptor expression and signaling correlate with poor prognosis. These findings highlight the pathway as a therapeutic target.
Immune evasion and tumor immunity
TGF-beta signaling suppresses type 2 immunity to cancer, contributing to immune evasion. Positive regulation of this pathway can therefore dampen anti-tumor immune responses. Understanding how GPR25 and other modulators influence T cell residency may provide new avenues for immunotherapy.
HCV-related hepatocellular carcinoma
Down-regulation of GHR/STAT5/IGF-1 signaling fosters aggressiveness of HCV-related hepatocellular carcinoma and crosstalks with type 2 TGF-beta receptor, suggesting that positive regulation of TGF-beta signaling contributes to disease progression.
From positive regulation of transforming growth factor beta receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate TGF-beta receptor signaling? | CRISPR knockout in HEK293T or cancer cell lines followed by SMAD phosphorylation assay |
| Does a specific point mutation in TGFBR1 affect its stability? | Point mutation knock-in using CRISPR in liver cancer cells |
| Does overexpression of GPR56 enhance TGF-beta signaling? | Overexpression cell model in HCC cells |
| Does GPR25 modulate TGF-beta signaling in T cells? | Knockout and overexpression in primary CD8 T cells |
| Does NODAL feedback regulate receptor activity? | Knock-in of tagged NODAL in cell lines |
| Does adaptor protein stabilization of TGFBR1 require ubiquitination sites? | Point mutation of ubiquitination sites in TGFBR1 |
How to Study the positive regulation of transforming growth factor beta receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on pathway activity | Identify novel positive regulators |
| Phospho-SMAD Western blot | SMAD2/3 phosphorylation levels | Quantify pathway activation |
| Luciferase reporter assay | Transcriptional activity of TGF-beta target genes | Validate positive regulators |
| Co-immunoprecipitation | Protein-protein interactions | Discover receptor-associated adaptors |
| RNA-seq | Transcriptional changes | Assess downstream effects of positive regulators |
| Proximity ligation assay | In situ protein interactions | Visualize receptor complex formation |
| Flow cytometry | Surface receptor expression | Measure TGFBR1/2 levels |
| CRISPR activation (CRISPRa) | Gain-of-function | Overexpress candidate positive regulators |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss reduces or enhances TGF-beta receptor signaling. This approach is powerful for discovering novel positive regulators. For example, knockout of TGFBR1 abolishes signaling, while knockout of negative regulators enhances it.
Phospho-SMAD immunoblotting
Western blotting for phosphorylated SMAD2/3 is a standard method to measure TGF-beta receptor signaling activity. Positive regulators increase phospho-SMAD levels upon ligand stimulation.
Transcriptional reporter assays
Luciferase reporters driven by TGF-beta-responsive promoters (e.g., SMAD-binding elements) quantify pathway activity. These assays are used to validate positive regulators identified in screens.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify proteins that interact with TGFBR1 or TGFBR2, revealing adaptors and stabilizers that positively regulate signaling.
How CRISPR Can Be Used to Study GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway
Knockout
CRISPR knockout of candidate genes is used to determine whether they are required for positive regulation of TGF-beta receptor signaling. For example, knocking out TGFBR1 abolishes signaling, while knocking out negative regulators enhances it. Knockout of GPR56 reduces HCC metastasis, confirming its positive role.
Point Mutation
Point mutations can be introduced to study specific residues critical for receptor stability or activity. For instance, mutating ubiquitination sites on TGFBR1 can reveal how adaptor proteins stabilize the receptor. Point mutations in SMAD2/3 phosphorylation sites can dissect signaling mechanisms.
Knock-in
Knock-in of tagged receptors or reporters allows real-time monitoring of pathway activity. Tagged TGFBR1 can be used to track receptor localization and turnover. Knock-in of fluorescent reporters driven by TGF-beta-responsive promoters enables live-cell imaging.
Overexpression
Overexpression of candidate positive regulators, such as GPR56 or adaptor proteins, can enhance TGF-beta signaling and drive phenotypes like metastasis. Overexpression models are useful for gain-of-function studies to confirm sufficiency.
How EDITGENE Supports positive regulation of transforming growth factor beta receptor signaling pathway Research
Researchers studying positive regulation of transforming growth factor beta receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in enhancing pathway activity. EDITGENE provides comprehensive CRISPR-based services to support such investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of transforming growth factor beta receptor signaling pathway research.
Frequently Asked Questions About positive regulation of transforming growth factor beta receptor signaling pathway
What is GO:0030511?
GO:0030511 is the Gene Ontology term for positive regulation of transforming growth factor beta receptor signaling pathway, describing any process that activates or increases TGF-beta receptor signaling activity.
What genes are involved in positive regulation of TGF-beta receptor signaling?
Key genes include TGFB1, TGFBR1, TGFBR2, SMAD2, SMAD3, SMAD4, GPR56, GPR25, and NODAL, among others.
How is TGF-beta receptor signaling positively regulated?
Positive regulation occurs through ligand binding, receptor stabilization by adaptors, SMAD phosphorylation, positive feedback loops, and crosstalk with other pathways.
What diseases are associated with dysregulated TGF-beta receptor signaling?
Cancer progression, metastasis, drug resistance, immune evasion, and HCV-related hepatocellular carcinoma are linked to aberrant positive regulation.
What experimental models are used to study GO:0030511?
CRISPR knockout, point mutation, knock-in, overexpression cell models, and CRISPR library screening are commonly used.
How does GPR56 promote TGF-beta signaling?
GPR56 facilitates hepatocellular carcinoma metastasis by enhancing the TGF-beta signaling pathway, likely through positive regulation at the receptor level.
What is the role of SMAD proteins in this pathway?
SMAD2 and SMAD3 are phosphorylated by activated TGFBR1, then complex with SMAD4 to translocate to the nucleus and regulate gene expression.
Can CRISPR screens identify positive regulators of TGF-beta signaling?
Yes, genome-wide CRISPR knockout or activation screens can uncover novel genes that positively regulate the pathway.
What is the prognostic relevance of TGF-beta receptor expression in glioblastoma?
TGF-beta receptor expression and signaling correlate with poor prognosis in glioblastoma, IDH-wildtype.
How does NODAL signaling involve positive feedback?
NODAL signaling propagation is regulated by receptor interactions and positive feedback, amplifying the signal.
Conclusion
GO:0030511, positive regulation of transforming growth factor beta receptor signaling pathway, is a critical biological process that amplifies TGF-beta signaling to control development, immunity, and disease. Its dysregulation drives cancer progression, metastasis, and immune evasion, making it a prime target for therapeutic intervention. CRISPR-based models are indispensable for dissecting the molecular players and mechanisms underlying this positive regulation. EDITGENE offers a comprehensive suite of services to support such research, from knockout and point mutation to overexpression and library screening.
References
- 1. Hata A et al.. 2016. TGF-β Signaling from Receptors to Smads.. Cold Spring Harb Perspect Biol 8(9) PMID: 27449815
- 2. Feng H et al.. 2025. GPR25 promotes the formation of lung and liver tissue-resident memory CD8 T cells.. Sci Immunol 10(113):eadu2089 PMID: 41270189
- 3. Togni C et al.. 2022. Prognostic Relevance of Transforming Growth Factor-β Receptor Expression and Signaling in Glioblastoma, Isocitrate Dehydrogenase-Wildtype.. J Neuropathol Exp Neurol 81(3):225-235 PMID: 35190826
- 4. Abu El-Makarem MA et al.. 2022. Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.. PLoS One 17(11):e0277266 PMID: 36374927
- 5. Liu K et al.. 2024. Stabilization of TGF-β Receptor 1 by a Receptor-Associated Adaptor Dictates Feedback Activation of the TGF-β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance.. Adv Sci (Weinh) 11(34):e2402327 PMID: 38981014
- 6. Liu M et al.. 2020. TGF-β suppresses type 2 immunity to cancer.. Nature 587(7832):115-120 PMID: 33087928
- 7. Luo Y et al.. 2024. GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-β signaling pathway.. Cell Death Dis 15(10):715 PMID: 39353900
- 8. Preiß H et al.. 2022. Regulation of Nodal signaling propagation by receptor interactions and positive feedback.. Elife 11 PMID: 36149406
